Logo Geneseeq
  • Products
    • Solid Tumors
      • Pan-Cancer
      • Cancer Type-Specific
      • Minimal Residual Disease
    • Hematologic Malignancies
      • Pan-Cancer
      • Cancer Type-Specific
    • Cancer Early Detection
    • Hereditary Cancers
  • Services
    • Central Lab Testing
    • Local Testing Solutions
      • IVD Kit Solutions
      • RUO Kit Solutions
    • Research Services
      • DNA Sequencing
      • RNA Sequencing
  • Technology
    • Our Technology
    • Publications
  • Partnerships
  • About Us
    • What is Precision Oncology?
    • Our Company
    • Our Team
    • Certificates & Accreditation
  • News
    • Newsroom
    • Geneseeq Blogs
  • Join Us
  • Contact Us
  • Search

May 21, 2025

Geneseeq Showcases Cutting-Edge Liquid Biopsy Research Across Multiple Cancer Types at ASCO 2025

by GENESEEQ

April 9, 2025

Geneseeq Technology Inc. to showcase seventeen studies at 2025 American Association for Cancer Research (AACR) annual meeting

by GENESEEQ

May 14, 2024

Geneseeq AT ASCO 2024

by GENESEEQ

March 6, 2024

Geneseeq to Showcase Twelve Studies at 2024 American Association for Cancer Research (AACR) Annual Meeting

by GENESEEQ

August 29, 2023

GENESEEQ TO SHARE EIGHT COLLABORATED STUDIES AT WCLC 2023

by Geneseeq

March 25, 2021

Genomic Study Uncovers New Biomarkers for the Efficacy of Immunotherapy in Nasopharyngeal Carcinoma (NPC) Patients 

by GENESEEQ

May 13, 2019

New biomarkers to predict patients’ clinical outcomes to ICI therapy in lung cancer

by GENESEEQ

Logo Geneseeq

1-647-714-5020
1-800-362-0325
info@geneseeq.ca

Quick Links
  • Services
  • Technology
  • News
  • About Us
Connect
  • Partnerships
  • Join us
  • Contact us
Privacy
  • Privacy Policy
  • Terms of Use
Headquarters

Main Office:
Suite 1802
393 University Avenue
Toronto, Ontario, M5G 1E6
Canada

© 2026 Geneseeq Technology Inc. | A Precision Oncology Company. All rights reserved

Privacy Preference Center

Privacy Preferences

    FDA Cleared IVD kit